265 related articles for article (PubMed ID: 22089617)
1. Pathophysiological insights in sickle cell disease.
Odièvre MH; Verger E; Silva-Pinto AC; Elion J
Indian J Med Res; 2011 Oct; 134(4):532-7. PubMed ID: 22089617
[TBL] [Abstract][Full Text] [Related]
2. Thrombosis and sickle cell disease.
De Franceschi L; Cappellini MD; Olivieri O
Semin Thromb Hemost; 2011 Apr; 37(3):226-36. PubMed ID: 21455857
[TBL] [Abstract][Full Text] [Related]
3. [Pathophysiology of sickle cell disease].
Elion J; Laurance S; Lapouméroulie C
Med Trop (Mars); 2010 Dec; 70(5-6):454-8. PubMed ID: 21520646
[TBL] [Abstract][Full Text] [Related]
4. Evolving treatment paradigms in sickle cell disease.
Jagadeeswaran R; Rivers A
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):440-446. PubMed ID: 29222291
[TBL] [Abstract][Full Text] [Related]
5. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
Nader E; Romana M; Connes P
Front Immunol; 2020; 11():454. PubMed ID: 32231672
[TBL] [Abstract][Full Text] [Related]
6. Developing treatment for sickle cell disease.
Steinberg MH; Brugnara C
Expert Opin Investig Drugs; 2002 May; 11(5):645-59. PubMed ID: 11996646
[TBL] [Abstract][Full Text] [Related]
7. Vascular pathophysiology of sickle cell disease.
Connes P; Renoux C; Joly P; Nader E
Presse Med; 2023 Dec; 52(4):104202. PubMed ID: 37944640
[TBL] [Abstract][Full Text] [Related]
8. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.
Kaul DK; Liu XD; Chang HY; Nagel RL; Fabry ME
J Clin Invest; 2004 Oct; 114(8):1136-45. PubMed ID: 15489961
[TBL] [Abstract][Full Text] [Related]
9. Novel permeability characteristics of red blood cells from sickle cell patients heterozygous for HbS and HbC (HbSC genotype).
Dalibalta S; Ellory JC; Browning JA; Wilkins RJ; Rees DC; Gibson JS
Blood Cells Mol Dis; 2010 Jun; 45(1):46-52. PubMed ID: 20227897
[TBL] [Abstract][Full Text] [Related]
10. Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.
Alapan Y; Kim C; Adhikari A; Gray KE; Gurkan-Cavusoglu E; Little JA; Gurkan UA
Transl Res; 2016 Jul; 173():74-91.e8. PubMed ID: 27063958
[TBL] [Abstract][Full Text] [Related]
11. Sickle cell disease: role of reactive oxygen and nitrogen metabolites.
Wood KC; Granger DN
Clin Exp Pharmacol Physiol; 2007 Sep; 34(9):926-32. PubMed ID: 17645642
[TBL] [Abstract][Full Text] [Related]
12. Established and experimental treatments for sickle cell disease.
De Franceschi L; Corrocher R
Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
[TBL] [Abstract][Full Text] [Related]
13. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment.
Piccin A; Murphy C; Eakins E; Rondinelli MB; Daves M; Vecchiato C; Wolf D; Mc Mahon C; Smith OP
Eur J Haematol; 2019 Apr; 102(4):319-330. PubMed ID: 30664257
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide loading reduces sickle red cell adhesion and vaso-occlusion in vivo.
McMahon TJ; Shan S; Riccio DA; Batchvarova M; Zhu H; Telen MJ; Zennadi R
Blood Adv; 2019 Sep; 3(17):2586-2597. PubMed ID: 31484636
[TBL] [Abstract][Full Text] [Related]
15. Sickle cell vaso-occlusion: The dialectic between red cells and white cells.
Conran N; Embury SH
Exp Biol Med (Maywood); 2021 Jun; 246(12):1458-1472. PubMed ID: 33794696
[TBL] [Abstract][Full Text] [Related]
16. Oxidative pathways in the sickle cell and beyond.
Alayash AI
Blood Cells Mol Dis; 2018 May; 70():78-86. PubMed ID: 28554826
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide pathology and therapeutics in sickle cell disease.
Kim-Shapiro DB; Gladwin MT
Clin Hemorheol Microcirc; 2018; 68(2-3):223-237. PubMed ID: 29614634
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiologically based drug treatment of sickle cell disease.
Steinberg MH
Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous polymerization and adhesion under hypoxia in sickle cell disease.
Papageorgiou DP; Abidi SZ; Chang HY; Li X; Kato GJ; Karniadakis GE; Suresh S; Dao M
Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9473-9478. PubMed ID: 30190429
[TBL] [Abstract][Full Text] [Related]
20. MEK1/2 inhibitors reverse acute vascular occlusion in mouse models of sickle cell disease.
Zhao Y; Schwartz EA; Palmer GM; Zennadi R
FASEB J; 2016 Mar; 30(3):1171-86. PubMed ID: 26631480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
